Fingolimod

Novartis recently announced positive results from the ACROSS study, which is assessing the clinical effect of Gilenya (fingolimod) in 10-year disability outcomes in people with relapsing-remitting multiple sclerosis (RRMS). The results were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Sept. 14-17 in London. The ACROSS study…

Scientists recently reported additional mechanisms of action that may underlie Gilenya (fingolimod) beneficial effects in relapsing-remitting multiple sclerosis (RRMS). The results were in an oral presentation, “Fingolimod therapy modulates B cell functions: reduces CXCR4-mediated migration and increases B cell -mediated anti-inflammatory cytokine profile,” given at the 32nd Congress of the European Committee for Treatment…

Multiple sclerosis patients are at risk of developing lymphopenia, or abnormally low levels of immune defense white blood cells, called lymphocytes, according to a study that investigated lymphocyte counts in people with relapsing MS both before and after the start of treatment. The study, “Lymphopenia in treatment-naive relapsing multiple…

Low-quality unauthorized generic versions of approved multiple sclerosis (MS) drugs can expose patients to danger, both through their toxic properties and a lack of efficacy that allows the disease to progress, researchers reported in the study, “Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod,” published…

Disease-modifying therapies, a group of treatments for people with relapsing-remitting multiple sclerosis (RRMS), work to stabilize patients’ cognitive functions just as they do their physical symptoms. Research, conducted over the course of a year, also reported no differences between two types of DMTs, Gilenya (fingolimod) and Tysabri (natalizumab). The study, “…

Fingolimod (Gilenya), a drug approved for patients with relapsing-remitting multiple sclerosis (RRMS) to prevent neuroinflammation, may also help these patients by directly enhancing nerve regeneration and increasing myelination in a way that is partly independent of its anti-inflammatory properties. The study reporting this finding, “Fingolimod promotes peripheral nerve regeneration…

Novel molecular imaging compounds that detect neuroinflammation in the brain of multiple sclerosis (MS) patients have been developed by researchers at the Washington University School of Medicine in Missouri, and may help to uncover the triggers of such inflammation and to better evaluate new disease treatments. The study, “Development and…

Researchers at the Swedish Neuroscience Institute in Washington and Novartis Pharma revealed that Gilenya (fingolimod) induced a consistent and significant reduction in disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). The results were recently presented at the June 1-4 Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual…

Rebound symptoms after stopping fingolimod (Gilenya) treatment affect a “clinically relevant” number of multiple sclerosis (MS) patients, a study by University of California, San Francisco, researchers reported. The study called attention to the need for determining the best method of sequencing or stopping MS treatments, and highlighted the need to identify factors…

Mabthera (rituximab), a widely approved drug for treating lymphoma and/or rheumatoid arthritis, is highly effective in treating multiple sclerosis (MS), researchers reported in an observational study in Sweden, where Mabthera is increasingly being used outside of its approved indications to treat relapsing-remitting MS patients. The study, published in the journal…

The immune system-suppressing multiple sclerosis (MS) drug fingolimod (Gilenya) also has potentially beneficial effects on the nervous system, according to a recent study, “The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.“  The article appeared online March 12 in an early version of the journal …

A new assessment by a European regulatory agency failed to find fingolimod of added benefit to comparator therapies for people with highly active relapsing-remitting multiple sclerosis (RRMS) who have failed to respond to treatment with at least one other disease-modifying drug. Fingolimod (Gilenya), developed as a therapy for multiple sclerosis, has undergone three early benefit assessments since its…

Stable multiple sclerosis (MS) patients do not appear to be at any increased risk of disease reactivation while switching to oral therapy following treatment with injectable interferon-β/glatiramer acetate (IFNβ/GA), a study reports. Recently published in the European Journal of Neurology, the Australian study was titled “Risk of early…

Premature infants are known to be at risk of cerebral injury due to oxygen deprivation and later problems with cognitive development, but an immunomodulating drug mostly used in the treatment of multiple sclerosis (MS) may be of help. Researchers in Germany and Switzerland reported that the drug fingolimod (Gilenya) prevented brain…

New research evaluating fingolimod’s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) largely supported its use, finding that the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies. The research article, “Efficacy and Safety of Fingolimod in an Unselected…

Akaal Pharma, a developer of small molecule drugs for the treatment of inflammation and autoimmune diseases including multiple sclerosis (MS), recently announced highly positive preclinical trial results on the safety and efficacy of its drug candidate AKP-11 when compared to Gilenya (fingolimod, FTY-720), an oral MS drug approved by…

The Multiple Sclerosis Society of New Zealand (MSNZ) announced that PHARMAC has agreed with its request to finance two novel first-in-line therapies for relapsing-remitting forms of multiple sclerosis (MS), making them accessible to patients there. PHARMAC recently agreed to fund the two treatments, teriflunomide (Aubagio), supplied by Sanofi-Aventis NZ, and dimethyl fumarate (Tecfidera),…

In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (Gilenya, Novartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that…

On October 8, 2015, data on two Phase III clinical trials called FREEDOMS and FREEDOMS II on Gilenya (fingolimod), a drug developed by Novartis, were presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain (October 7-10).

A review study recently published in the journal Cochrane Database of Systematic Review (CDSR) focused on the clinical benefit of different therapies available for relapsing-remitting multiple sclerosis (RRMS). The study is entitled “Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis” and was led…

An encouraging new analysis reveals that fingolimod is an effective multiple sclerosis (MS) therapy for a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centers. MS is a chronic, progressive neurodegenerative disorder that is the result of an attack on the central nervous system…

Fingolimod, also known by its brand name Gilenya, is an oral immunotherapy approved for the treatment of relapsing-remitting multiple sclerosis (MS). In a recent study published in the Journal PLOS One, a team of researchers found that the autonomic cardiovascular dysfunction in MS patients with delayed heart ratere-acceleration…

A new study recently published in the Journal of Neurology, Neurosurgery and Psychiatry revealed that long-term fingolimod therapy (marketed as Gilenya by Novartis) can maintain a low disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). The study was conducted by an international team of researchers and…

An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from natalizumab to fingolimod therapy. The study was recently published…

Novartis International recently provided an update on its fingolimod Phase III trial evaluating the use of the drug in primary progressive multiple sclerosis (PPMS), reporting that the study did not reveal any significant benefits of prescribing fingolimod over a placebo. However, results regarding…

This past Wednesday, September 10th, the largest, most anticipated multiple sclerosis (MS) convention — the 6th Joint ACTRIMS-ECTRIMS Triennial Meeting, MSBoston 2014 — kicked off with a whopping 8,000 registered attendees, all eager to learn more about the latest developments in MS. One of the highlights of the event…

Those attending this week’s ACTRIMS-ECTRIMS convention set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical company Novartis to present promising findings on Gilenya (fingolimod) — the company’s leading oral formulation for relapsing-remitting multiple sclerosis (RRMS). In previously completed studies and clinical trials,…

Fingolimod is a disease modifying therapy (DMT) used to treat relapsing remitting multiple sclerosis (RRMS) patients as well as patients who continue to present with relapses despite treatment with beta interferon drugs, and is the first oral medication to be approved by the U.S. Food and Drug…

A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…